Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Guided Therapeutics (GTHP) over the last 16 years, with Q3 2025 value amounting to $952000.0.

  • Guided Therapeutics' Accumulated Expenses rose 314.19% to $952000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $952000.0, marking a year-over-year increase of 314.19%. This contributed to the annual value of $1.0 million for FY2024, which is 533.71% down from last year.
  • Latest data reveals that Guided Therapeutics reported Accumulated Expenses of $952000.0 as of Q3 2025, which was up 314.19% from $1.1 million recorded in Q2 2025.
  • Guided Therapeutics' Accumulated Expenses' 5-year high stood at $4.9 million during Q1 2021, with a 5-year trough of $780000.0 in Q1 2024.
  • In the last 5 years, Guided Therapeutics' Accumulated Expenses had a median value of $1.1 million in 2025 and averaged $1.3 million.
  • Per our database at Business Quant, Guided Therapeutics' Accumulated Expenses soared by 6717.9% in 2021 and then crashed by 7491.32% in 2022.
  • Over the past 5 years, Guided Therapeutics' Accumulated Expenses (Quarter) stood at $1.8 million in 2021, then fell by 29.47% to $1.2 million in 2022, then decreased by 14.35% to $1.1 million in 2023, then decreased by 5.34% to $1.0 million in 2024, then decreased by 5.84% to $952000.0 in 2025.
  • Its Accumulated Expenses stands at $952000.0 for Q3 2025, versus $1.1 million for Q2 2025 and $1.1 million for Q1 2025.